Back to Search Start Over

Caloric restriction coupled with radiation decreases metastatic burden in triple negative breast cancer.

Authors :
Simone BA
Dan T
Palagani A
Jin L
Han SY
Wright C
Savage JE
Gitman R
Lim MK
Palazzo J
Mehta MP
Simone NL
Source :
Cell cycle (Georgetown, Tex.) [Cell Cycle] 2016 Sep; Vol. 15 (17), pp. 2265-74. Date of Electronic Publication: 2016 Mar 30.
Publication Year :
2016

Abstract

Purpose: Metastatic breast cancer is devastating and triple negative breast cancers (TNBC) have a higher propensity for metastasis. Improved local control upfront in this aggressive cancer could potentially decrease its propensity toward metastasis. We sought to determine if using caloric restriction (CR) as a systemic therapy, combined with radiation therapy (IR) to the primary tumor, may impact metastatic disease.<br />Methods: An orthotopic mouse model using a highly metastatic, luciferase-tagged TNBC cell line (4T1), was used to generate palpable tumors. Mice were then treated with CR, IR, and a combination of the two. In vivo imaging was performed for metastatic evaluation. Molecular evaluation of the tumors was performed, generating a mechanistic hypothesis for CR, which was then tested with pertinent pathway inhibition in the model.<br />Results: CR significantly increased the time to developing metastases, decreased the overall number and volume of lung metastases, and increased survival. CR decreased proliferation, increased apoptosis and globally downregulated the IGF-1R signaling pathway. Adding an IGF-1R/INSR inhibitor to local IR in vivo accomplished a decrease in metastases similar to CR plus IR, demonstrating the importance of the IGF-1R signaling pathway, and underscoring it as a possible mechanism for CR.<br />Conclusions: CR decreased metastatic burden and therefore may complement cytotoxic therapies being used in the clinical setting for metastatic disease. Downregulation of the IGF-1R pathway, is in part responsible for this response and modulating IGF-1R directly resulted in similar improved progression-free survival. The novel use of CR has the potential to enhance clinical outcomes for patients with metastatic breast cancer.

Details

Language :
English
ISSN :
1551-4005
Volume :
15
Issue :
17
Database :
MEDLINE
Journal :
Cell cycle (Georgetown, Tex.)
Publication Type :
Academic Journal
Accession number :
27027731
Full Text :
https://doi.org/10.1080/15384101.2016.1160982